Efficacy and complications of dose increments of botulinum toxin-A in the treatment of horizontal comitant strabismus.
OBJECTIVE
To investigate the efficacy and complications associated with dose increments of botulinum toxin-A (BTA) for comitant horizontal strabismus patients.


METHODS
Twenty-five esotropic (ET) and 45 exotropic (XT) patients received 2.5-20 U of BTA injection. Parameters for achieving less than 10 prism dioptres (pd) of horizontal deviation and percentage correction of the pretreatment deviation were assessed for injections of less than 10 U and more than 10 U of BTA. Induced ptosis and vertical deviation were examined within and after 6 months of follow-up.


RESULTS
The mean pretreatment deviations were 38.6 +/- 2.5 pd and 37.6 +/- 1.9 pd for the ET and XT groups, respectively. After receiving 1.6 and 1.5 injections on average, improvement to less than 10 pd at the primary position occurred in 32% of ET and 22% of XT patients; the difference was not statistically significant. The percentage corrections of the ET patients were 41.4 +/- 9.3% and 36.9 +/- 5.6% in those treated with less than 10 U and more than 10 U of BTA respectively; the difference between the two groups was insignificant. For the XT patients the values were 42.1 +/- 7.4% and 28.9 +/- 3.5% respectively, which also were not statistically significantly different. Frequency of induced ptosis was more common in ET than XT patients (p = 0.01) and this difference was more pronounced with increased doses of BTA (7.7% in ET and 5.3% in XT patients with less than 10 U of BTA, and 24.0% in ET and 4.3% in XT patients with more than 10 U of BTA). Ptosis resolved completely within 6 weeks in all cases. Induced vertical deviation with less than 10 U of BTA was encountered in one case of ET (11.1%, 9 pd) and in another case of XT (8.3%, 4 pd), increasing to 60.0% (2-20 pd) and 38.8% (4-16 pd) respectively with more than 10 U of BTA injection. In about a year, induced vertical deviation resolved in approximately 40%, and decreased in 30% of the cases.


CONCLUSIONS
Increasing the dose of BTA is clinically effective in larger deviations, although statistically indifferent, especially in ET compared with XT. However, an increased dose is accompanied by increased incidence of induced ptosis and vertical deviation. Ptosis is temporary, but vertical deviation may persist for a long time and may present a cosmetic problem for some patients when more than 10 U of BTA is used.
Sener
E C
EC
Department of Ophthalmology, Hacettepe University Hospitals, Ankara, Turkey. ecsener@hacettepe.edu.tr
Sanaç
A S
AS
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001763:Blepharoptosis / Q000139:chemically induced; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004576:Electromyography; D004948:Esotropia / Q000628:therapy*; D005099:Exotropia / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
D019274:Botulinum Toxins, Type A